Systemic lupus erythematosus and lupus nephritis market to reach $5.9 billion in 7MM by 2034
The systemic lupus erythematosus (SLE) and lupus nephritis (LN) market across the seven major markets (7MM: the USA, France, Germany, Italy, Spain, the UK, and Japan) is forecast to grow from $2.4 billion in 2024 to $5.9 billion in 2034, at a compound annual growth rate (CAGR) of 9.6%.
GlobalData’s latest report, “Systemic Lupus Erythematosus and Lupus Nephritis: Seven-Market Drug Forecast and Market Analysis 2024–34”, reveals that the growth will be mainly driven by the new entries of nine pipeline agents targeting disease modification, representing a shift in a market that was predominantly dominated by the off-label use of steroids, wide-spectrum immunosuppressants, and antimalarials. The shift is expected to significantly improve safety, efficacy, and thus treatment outcomes and quality of life of SLE and LN patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze